摘要
目的比较曲唑酮与丁螺环酮治疗广泛性焦虑障碍的疗效及安全性。方法将符合《美国精神障碍诊断与统计手册第四版》(DSM-Ⅳ)诊断标准的84例广泛性焦虑障碍病人随机分为曲唑酮组(n= 43,50～200 mg·d^(-1))和丁螺环酮组(n=41,25～45 mg·d^(-1)),开放治疗6wk,于治疗前和治疗后wk1、2、4、6以汉密尔顿焦虑量表(HAMA)、焦虑自评量表(SAS)、临床疗效总评(CGI-I)和副反应量表(TESS)评定疗效和安全性。结果曲唑酮组有效率91%,显效率72%;丁螺环酮组有效率88%,显效率71%,2组疗效比较差异无显著意义(Ridit分析,P>0.05)。曲唑酮组在1wk末HAMA评分显著低于治疗前(经秩和检验,P<0.05)。治疗6wk末曲唑酮组HAMA的躯体焦虑因子分与丁螺环酮组比较差异有显著意义(经秩和检验,P<0.05)。2组TESS评分(3.5±s 1.8)分和(4.0±1.9)分,经比较差异无显著意义(经秩和检验,P>0.05)。结论曲唑酮是治疗广泛性焦虑障碍安全有效的药物,疗效与丁螺环酮相似,对躯体焦虑症状疗效优于丁螺环酮,曲唑酮起效较快。
AIM To evaluate the efficacy and safety of trazodone and buspirone in the treatment of generalized anxiety disorder. METHODS Eighty-four patients suffered from generalized anxiety disorder met with the criteria of DSM-Ⅳ were randomly assigned to receive trazodone （n = 43, 50 - 200 mg ·d^-1） and buspirone （n = 41, 25 - 45 mg·d^-1）, two groups HAMA, SAS, CGI-SI and TESS were adopted to evaluate the efficacy and safety before and after 6 wk of the treatment, respectively. RESULTS Effectual and effective rates of trazodone group and buspirone group were 91% and 72 % ; 88 % and 71%, respectivel （ Ridit analysis, P 〉 0.05）. There was no significant difference between the two groups. By the end of 1st week, the improvement was significant in the trazodone group than that of buspirone group （Wilcoxon signed ranks test, P 〈0.05）, indicating the faster effects. At the end of 6th week, the Physical Anxiety Factor scores of HAMA were lower in trazodone group than those of buspirone group （Wilcoxon signed ranks test, P 〈 0.05） . The adverse reactions of both groups were mild and didn＇ t need special handling. CONCLUSION Trazodone is a safe and effective drug in the treatment of generalized anxiety disorder, with faster effects and similar than that of buspirone.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2008年第11期832-835,共4页
Chinese Journal of New Drugs and Clinical Remedies
关键词
曲唑酮
丁螺环酮
药物疗法
随机对照研究
广泛性焦虑摩碍
trazodone
buspirone
drug therapy
randomized controlled trials
generalized anxiety disorder
